Marizyme, Inc. (MRZM)
Market Cap | 7.02M |
Revenue (ttm) | 549,691 |
Net Income (ttm) | -69.02M |
Shares Out | 131.79M |
EPS (ttm) | -1.39 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 25,881 |
Open | 0.0930 |
Previous Close | 0.0541 |
Day's Range | 0.0533 - 0.0930 |
52-Week Range | 0.0500 - 0.4100 |
Beta | 0.21 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About MRZM
Marizyme, Inc., a multi-technology biomedical company, develops and commercializes medical technologies to enhances patients health. It's product portfolio includes DuraGraft, a first-in-class, De Novo granted and CE marked intra-operative vascular graft storage and flushing solution used during coronary artery bypass graft (CABG) surgeries; MATLOC, a point-of-care, lab-on-chip technology platform, developed for quantitative chronic kidney disease assessment; and Krillase, a protein enzyme that acts to break protein bonds and has applications i... [Read more]
Financial Performance
In 2023, Marizyme's revenue was $645,810, an increase of 176.60% compared to the previous year's $233,485. Losses were -$65.35 million, 5.10% more than in 2022.
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/x/v/press15-2373039.jpg)
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, ...
![](https://cdn.snapi.dev/images/v1/z/p/press17-2115189.jpg)
Marizyme CEO Delivers Business Update
JUPITER, FL, Oct. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), today provided the following business update to the stockholders and the i...
![](https://cdn.snapi.dev/images/v1/b/s/press11-2093079.jpg)
Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™
DuraGraft is the first and only FDA cleared medical device for use as an intra-operative vascular conduit storage and flushing solution used during CABG surgeries
![](https://cdn.snapi.dev/images/v1/y/u/press4-1882005.jpg)
Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products
JUPITER, FL, May 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), a multi-technology biomedical company focused on the accelerated developmen...
![](https://cdn.snapi.dev/images/v1/6/q/press11-1172776.jpg)
Marizyme Announces Allowance of Patent Application for Flagship Product DuraGraft by United States Patent and Trademark Office
Jupiter, FL, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. (“Marizyme” or the “Company”) (OTCQB: MRZM) is pleased to announce that the United States Patent and Trademark Office ...
![](https://cdn.snapi.dev/images/v1/e/c/press10-1162416.jpg)
Marizyme Announces the Closing of My Health Logic Acquisition Along With Initial Financing
JUPITER, Fla., Dec. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the closing of its acquisition of My Health Logic ...
![](https://cdn.snapi.dev/images/v1/5/n/press3-1136170.jpg)
Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress
JUPITER, FL, Dec. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of products to prevent, treat and diagn...
![](https://cdn.snapi.dev/images/v1/n/d/press19-1135391.jpg)
Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories
Jupiter, FL, Dec. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of advanced healthcare products to p...
![](https://cdn.snapi.dev/images/v1/c/q/conf20-1111385.jpg)
Marizyme is Pleased to Announce the Appointment of David Barthel as CEO
JUPITER, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the hiring of Mr. David Barthel as the Chief Execu...
![](https://cdn.snapi.dev/images/v1/c/2/press20-746468.jpg)
Marizyme, Inc. Issues Letter to Shareholders
JUPITER, Fla., March 31, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB: MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in ti...
![](https://cdn.snapi.dev/images/v1/3/p/press3-707717.jpg)
Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera
JUPITER, Fla., March 4, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tiss...
![](https://cdn.snapi.dev/images/v1/7/9/press6---qv3bzhppfl.jpg)
Marizyme, Inc. Strengthens Senior Management Team with Two Appointments: Roger Schaller EVP, Commercial Operations and Amy Chandler, EVP, Regulatory Affairs and Quality Management Systems
JUPITER, Fla., Feb. 1, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissu...
![](https://cdn.snapi.dev/images/v1/z/o/press19---nsusd7pjyv.jpg)
Marizyme Announces Approval for DuraGraft® in India
JUPITER, Fla., Jan. 14, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tiss...
![](https://cdn.snapi.dev/images/v1/c/d/press20---sv21zvkflv.jpg)
Marizyme Announces the Use of DuraGraft® as the Standard-of-Care in Patients Undergoing Coronary Artery Bypass Surgery (CABG) at Vienna Heart Center North Floridsdorf
JUPITER, Fla., Jan. 11, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB: MRZM), a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, or...
![](https://cdn.snapi.dev/images/v1/c/o/conf7---gmk5lnjghm.jpg)
Marizyme, Inc. to Present at Biotech Showcase 2021 During the J.P. Morgan Healthcare Conference Biotech Showcase Digital, BIO @ JPM During "J.P.
JUPITER, Fla., Jan. 7, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissu...